Capstone Investment Advisors
NAUT icon

Capstone Investment Advisors’s Nautilus Biotechnolgy NAUT Stock Holding History

Capstone Investment Advisors’s Portfolio NAUT Stock Details NAUT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-20,672
Closed -$127K – 2008
2021
Q3 		$127K Buy
+20,672
New +$165K ﹤0.01% 1753

Other funds holding NAUT

PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
MVG
Madrona Venture Group Seattle, Washington $22.1M AUM 86.9% 1-Year Est. Return
AEPBI
AH Equity Partners Bio II Menlo Park, California $144M AUM 54.61% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
CFM
Comprehensive Financial Management Los Gatos, California $3.05B AUM 1.77% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
ACI
Amazon.com Inc Seattle, Washington $4.42B AUM 22.6% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
AI
ArchPoint Investors Coral Gables, Florida $473M AUM 49.24% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Capstone Investment Advisors's NAUT Position: Q4 2021 in Review

Capstone Investment Advisors sold out of Nautilus Biotechnolgy (NAUT) in Q4 2021, closing a stake of 20,672 shares — an estimated $127K sold.

Capstone Investment Advisors first reported a position in NAUT in Q3 2021 and held it in 1 quarter. The position peaked at $127K in Q3 2021. 81 funds tracked by Wall St. Rank hold NAUT as of Q4 2021.

  • Capstone Investment Advisors reported no remaining Nautilus Biotechnolgy position as of Q4 2021 after selling out during the quarter.
  • Capstone Investment Advisors sold 20,672 Nautilus Biotechnolgy shares in Q4 2021, an estimated $127K.
  • Capstone Investment Advisors first reported a position in Nautilus Biotechnolgy in Q3 2021 and held it in 1 quarter.
  • Capstone Investment Advisors's Nautilus Biotechnolgy position peaked at $127K in Q3 2021.
  • 81 funds tracked by Wall St. Rank held Nautilus Biotechnolgy as of Q4 2021.

Based on Capstone Investment Advisors's 13F filing for Q4 2021, filed 11 Feb 2022.